Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells

Chih Yi Chen, Hsin Yuan Fang, Shiow Her Chiou, Shih En Yi, Chih Yang Huang, Shu Fen Chiang, Hui Wen Chang, Tze Yi Lin, I. Ping Chiang, Kuan Chih Chow

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

By screening mouse monoclonal antibody libraries for Kelch repeats, we serendipitously identified monoclonal antibodies to eukaryotic elongation factor 2 (eEF2). Interestingly, eEF2 was highly expressed in lung adenocarcinoma (LADC), but not in the neighboring non-tumor lung tissue. Normally, eEF2 is involved in the peptidyl-tRNA translocation during protein synthesis. Overexpression of eEF2 would implicate an association with disease progression of LADC. In the present study, we investigated the prognostic significance of eEF2 in patients with LADC. Expression of eEF2 was detected by immunoblotting, immunohistochemistry and confocal immunofluorescence microscopy. Our results show that patients with high eEF2 expression had a significantly higher incidence of early tumor recurrence (67.8%vs 18.2%, P=0.016), and a significantly worse prognosis (P<0.001). In an in vitro study, silencing of eEF2 expression increased mitochondrial elongation, cellular autophagy and cisplatin sensitivity. Moreover, eEF2 was sumoylated in LADC cells, and eEF2 sumoylation correlated with drug resistance. These results suggest that eEF2 is an anti-apoptotic marker in LADC. However, biological function and involvement of eEF2 in the disease progression of LADC require further studies.

Original languageEnglish (US)
Pages (from-to)1582-1589
Number of pages8
JournalCancer science
Volume102
Issue number8
DOIs
StatePublished - Aug 1 2011

Fingerprint

Peptide Elongation Factor 2
Sumoylation
Protein Stability
Disease Progression
Adenocarcinoma of lung
Monoclonal Antibodies
Autophagy
Eukaryotic Cells
Protein Transport
Fluorescence Microscopy
Immunoblotting
Drug Resistance
Confocal Microscopy
Cisplatin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells. / Chen, Chih Yi; Fang, Hsin Yuan; Chiou, Shiow Her; Yi, Shih En; Huang, Chih Yang; Chiang, Shu Fen; Chang, Hui Wen; Lin, Tze Yi; Chiang, I. Ping; Chow, Kuan Chih.

In: Cancer science, Vol. 102, No. 8, 01.08.2011, p. 1582-1589.

Research output: Contribution to journalArticle

Chen, Chih Yi ; Fang, Hsin Yuan ; Chiou, Shiow Her ; Yi, Shih En ; Huang, Chih Yang ; Chiang, Shu Fen ; Chang, Hui Wen ; Lin, Tze Yi ; Chiang, I. Ping ; Chow, Kuan Chih. / Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells. In: Cancer science. 2011 ; Vol. 102, No. 8. pp. 1582-1589.
@article{f814bf2ec0bf4738a24ddf082b9da64d,
title = "Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells",
abstract = "By screening mouse monoclonal antibody libraries for Kelch repeats, we serendipitously identified monoclonal antibodies to eukaryotic elongation factor 2 (eEF2). Interestingly, eEF2 was highly expressed in lung adenocarcinoma (LADC), but not in the neighboring non-tumor lung tissue. Normally, eEF2 is involved in the peptidyl-tRNA translocation during protein synthesis. Overexpression of eEF2 would implicate an association with disease progression of LADC. In the present study, we investigated the prognostic significance of eEF2 in patients with LADC. Expression of eEF2 was detected by immunoblotting, immunohistochemistry and confocal immunofluorescence microscopy. Our results show that patients with high eEF2 expression had a significantly higher incidence of early tumor recurrence (67.8{\%}vs 18.2{\%}, P=0.016), and a significantly worse prognosis (P<0.001). In an in vitro study, silencing of eEF2 expression increased mitochondrial elongation, cellular autophagy and cisplatin sensitivity. Moreover, eEF2 was sumoylated in LADC cells, and eEF2 sumoylation correlated with drug resistance. These results suggest that eEF2 is an anti-apoptotic marker in LADC. However, biological function and involvement of eEF2 in the disease progression of LADC require further studies.",
author = "Chen, {Chih Yi} and Fang, {Hsin Yuan} and Chiou, {Shiow Her} and Yi, {Shih En} and Huang, {Chih Yang} and Chiang, {Shu Fen} and Chang, {Hui Wen} and Lin, {Tze Yi} and Chiang, {I. Ping} and Chow, {Kuan Chih}",
year = "2011",
month = "8",
day = "1",
doi = "10.1111/j.1349-7006.2011.01975.x",
language = "English (US)",
volume = "102",
pages = "1582--1589",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells

AU - Chen, Chih Yi

AU - Fang, Hsin Yuan

AU - Chiou, Shiow Her

AU - Yi, Shih En

AU - Huang, Chih Yang

AU - Chiang, Shu Fen

AU - Chang, Hui Wen

AU - Lin, Tze Yi

AU - Chiang, I. Ping

AU - Chow, Kuan Chih

PY - 2011/8/1

Y1 - 2011/8/1

N2 - By screening mouse monoclonal antibody libraries for Kelch repeats, we serendipitously identified monoclonal antibodies to eukaryotic elongation factor 2 (eEF2). Interestingly, eEF2 was highly expressed in lung adenocarcinoma (LADC), but not in the neighboring non-tumor lung tissue. Normally, eEF2 is involved in the peptidyl-tRNA translocation during protein synthesis. Overexpression of eEF2 would implicate an association with disease progression of LADC. In the present study, we investigated the prognostic significance of eEF2 in patients with LADC. Expression of eEF2 was detected by immunoblotting, immunohistochemistry and confocal immunofluorescence microscopy. Our results show that patients with high eEF2 expression had a significantly higher incidence of early tumor recurrence (67.8%vs 18.2%, P=0.016), and a significantly worse prognosis (P<0.001). In an in vitro study, silencing of eEF2 expression increased mitochondrial elongation, cellular autophagy and cisplatin sensitivity. Moreover, eEF2 was sumoylated in LADC cells, and eEF2 sumoylation correlated with drug resistance. These results suggest that eEF2 is an anti-apoptotic marker in LADC. However, biological function and involvement of eEF2 in the disease progression of LADC require further studies.

AB - By screening mouse monoclonal antibody libraries for Kelch repeats, we serendipitously identified monoclonal antibodies to eukaryotic elongation factor 2 (eEF2). Interestingly, eEF2 was highly expressed in lung adenocarcinoma (LADC), but not in the neighboring non-tumor lung tissue. Normally, eEF2 is involved in the peptidyl-tRNA translocation during protein synthesis. Overexpression of eEF2 would implicate an association with disease progression of LADC. In the present study, we investigated the prognostic significance of eEF2 in patients with LADC. Expression of eEF2 was detected by immunoblotting, immunohistochemistry and confocal immunofluorescence microscopy. Our results show that patients with high eEF2 expression had a significantly higher incidence of early tumor recurrence (67.8%vs 18.2%, P=0.016), and a significantly worse prognosis (P<0.001). In an in vitro study, silencing of eEF2 expression increased mitochondrial elongation, cellular autophagy and cisplatin sensitivity. Moreover, eEF2 was sumoylated in LADC cells, and eEF2 sumoylation correlated with drug resistance. These results suggest that eEF2 is an anti-apoptotic marker in LADC. However, biological function and involvement of eEF2 in the disease progression of LADC require further studies.

UR - http://www.scopus.com/inward/record.url?scp=79960392650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960392650&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2011.01975.x

DO - 10.1111/j.1349-7006.2011.01975.x

M3 - Article

C2 - 21554491

AN - SCOPUS:79960392650

VL - 102

SP - 1582

EP - 1589

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 8

ER -